chronic prurigo

Don't rely on leaderboards alone.

Let's move to chronic prurigo.

There's a Delphi consensus from Mendes-Bastos and colleagues in dermatology and therapy, and it's timely because we now have targeted biologics, dupilumab and nemolizumab, tested for this condition.

The diagnostic criteria are clear.